07:37 AM EDT, 07/08/2024 (MT Newswires) -- Kineta ( KA ) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.

VISTA blocking monoclonal antibody is currently being evaluated in a phase 1/phase 2 clinical trial for patients with advanced solid tumors.

The exclusive right will continue either to the execution of any definitive agreement with TuHURA or by Oct. 1, subject to extension, Kineta ( KA ) said.

Kineta ( KA ) shares were nearly 20% higher in premarket trading.

Price: 0.7229, Change: +0.12, Percent Change: +19.13